Scarica l'app Stockscreener
224.09
0.56%
1.24
Dopo l'orario di chiusura:
221.44
-2.65
-1.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$222.85
Aprire:
$220.99
Volume 24 ore:
642.72K
Relative Volume:
0.60
Capitalizzazione di mercato:
$32.65B
Reddito:
$5.40B
Utile/perdita netta:
$1.49B
Rapporto P/E:
22.15
EPS:
10.1168
Flusso di cassa netto:
$1.78B
1 W Prestazione:
+0.71%
1M Prestazione:
-12.94%
6M Prestazione:
-19.00%
1 anno Prestazione:
+0.49%
Intervallo 1D:
$219.01
$226.30
Intervallo di 1 settimana:
$218.39
$226.30
Portata 52W:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
224.09 | 32.65B | 5.40B | 1.49B | 1.78B | 10.12 |
ISRG
Intuitive Surgical Inc
|
452.07 | 160.56B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
154.51 | 43.95B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
74.56 | 36.34B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
44.28 | 35.94B | 28.43B | 1.16B | 1.26B | 1.4457 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Iniziato | Citigroup | Buy |
| 2025-09-02 | Aggiornamento | CLSA | Hold → Outperform |
| 2025-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
Wealth Enhancement Advisory Services LLC Has $1.66 Million Stock Holdings in ResMed Inc. $RMD - MarketBeat
Element Squared LLC Buys Shares of 6,067 ResMed Inc. $RMD - MarketBeat
Aberdeen Group Reduces Stake in ResMed Inc. - National Today
Aberdeen Group plc Sells 37,737 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. (NYSE:RMD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Insider Sell: Brett Sandercock Sells Shares of ResMed Inc (RMD) - GuruFocus
RESMED INC. R (RME.MU) Q1 FY2025 earnings call transcript - Yahoo Finance
Resmed CFO Sandercock sells $224k in stock By Investing.com - Investing.com South Africa
Resmed CFO Sandercock sells $224k in stock - Investing.com
ResMed (RMD) CFO Sandercock sells 1,000 shares in open market trade - Stock Titan
J. Safra Sarasin Holding AG Sells 10,794 Shares of ResMed Inc. $RMD - MarketBeat
Spire Wealth Management Cuts Stock Holdings in ResMed Inc. $RMD - MarketBeat
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus
ResMed Inc. (RMD) stock price, news, quote and history - Yahoo Finance UK
ResMed Inc. (RMD.AX) stock price, news, quote and history - Yahoo Finance Singapore
Insider Selling: ResMed (NYSE:RMD) Director Sells 2,000 Shares of Stock - MarketBeat
ResMed Inc. (RMD) latest stock news and headlines - Yahoo Finance Singapore
Resmed director Farrell sells $450,000 in stock By Investing.com - Investing.com India
Resmed director Farrell sells $450,000 in stock - Investing.com
Resmed Insider Sold Shares Worth $450,000, According to a Recent SEC Filing - MarketScreener
ResMed (NYSE: RMD) director sells 2,000 shares under Rule 10b5-1 plan - Stock Titan
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance UK
Peter C. Farrell (RMD) sells 6,000 shares via Rule 144 notices (NYSE: RMD) - Stock Titan
Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026 - The Manila Times
Resmed to post quarterly results after market close on April 30 - Stock Titan
Affiliate proposes three 1,000-share sales for RMD (NYSE: RMD) — broker listed - Stock Titan
ResMed Inc. stock rises Tuesday, still underperforms market - MarketWatch
Is It Time To Revisit ResMed (RMD) After Recent Share Price Weakness? - Yahoo Finance
ResMed (RMD) Valuation Check After Recent Share Price Weakness - Sahm
ResMed back on the Buy List - intelligentinvestor.com.au
ResMed Earnings Preview: What to Expect - Yahoo Finance
SG Americas Securities LLC Cuts Stock Position in ResMed Inc. $RMD - MarketBeat
Eagleford Energy and ResMed Compared - National Today
ResMed Inc. Stock: Navigating Sleep Apnea Market Leadership Amid Demographic Tailwinds and Digital I - AD HOC NEWS
ResMed Inc. (RMD) Launches Global Sleep Institute at World Sleep Congress - MSN
RBC Capital Maintains ResMed Inc.Depositary Receipt (RSMDF) Outperform Recommendation - MSN
ResMed stock price forecast: technical weakness persists as RMD struggles below key moving averages - Traders Union
Vanguard (RMD) disaggregates holdings; reports zero ownership in ResMed - Stock Titan
Regatta Capital Group LLC Invests $2.51 Million in ResMed Inc. - nationaltoday.com
Regatta Capital Group LLC Takes $2.51 Million Position in ResMed Inc. $RMD - MarketBeat
ResMed & Netwealth: A Fresh Look at Valuation Trends - Kalkine Media
Dakota Wealth Management Has $8.18 Million Holdings in ResMed Inc. $RMD - MarketBeat
Assenagon Asset Management S.A. Has $19.43 Million Stock Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock outperforms market despite losses on the day - MarketWatch
ResMed Inc. stock: Leader in sleep and respiratory care with strong North American market presence - AD HOC NEWS
Unpacking Q4 Earnings: ResMed (NYSE:RMD) In The Context Of Other Patient Monitoring Stocks - Yahoo Finance
Is ResMed stock underperforming the Nasdaq? - MSN
ResMed Inc. (RMD.AX) Alternative Data AnalyticsSocial & Digital Signals - Meyka
ResMed Inc stock faces pressure amid slowing sleep apnea device demand and insurance reimbursement h - AD HOC NEWS
ResMed Share Price Insights: Is RMD Worth Watching in 2026? - Kalkine Media
ResMed Inc. stock faces pressure amid weak performance and uncertain outlook in sleep apnea market - AD HOC NEWS
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
1.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):